logo
Citi Trends Sets Date for Second Quarter 2025 Earnings Release and Conference Call

Citi Trends Sets Date for Second Quarter 2025 Earnings Release and Conference Call

Business Wire8 hours ago
SAVANNAH, Ga.--(BUSINESS WIRE)--Citi Trends, Inc. (NASDAQ: CTRN) today announced plans to release its earnings for the second quarter 2025 before the market opens on Tuesday, August 26, 2025. Citi Trends will host a conference call on the same day at 9:00 a.m. ET.
A live broadcast of Citi Trends' conference call will be available online at the Company's website, www.cititrends.com, under the Investor Relations section, on August 26, 2025, beginning at 9:00 a.m. ET. The online replay will follow shortly after the call and will be available for one year. The live conference call can also be accessed by dialing 1-877-407-0779.
During the conference call, the Company may discuss and answer questions concerning business and financial developments and trends that have occurred after quarter-end. The Company's responses to questions, as well as other matters discussed during the conference call, may contain or constitute information that has not been disclosed previously.
About Citi Trends
Citi Trends, Inc. is a leading off-price value retailer of apparel, accessories and home trends primarily for African American families in the United States. The Company operates 590 stores located in 33 states. For more information, visit www.cititrends.com or your local store.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Inspire Medical Systems, UFP Technologies, Globus Medical, Neogen, and Dentsply Sirona Shares Skyrocket, What You Need To Know
Inspire Medical Systems, UFP Technologies, Globus Medical, Neogen, and Dentsply Sirona Shares Skyrocket, What You Need To Know

Yahoo

time22 minutes ago

  • Yahoo

Inspire Medical Systems, UFP Technologies, Globus Medical, Neogen, and Dentsply Sirona Shares Skyrocket, What You Need To Know

What Happened? A number of stocks jumped in the afternoon session after positive inflation data fueled hopes for an interest rate cut by the Federal Reserve. The latest Consumer Price Index (CPI) report showed inflation rose by a modest 0.2% in July and 2.7% over the last year. This cooler-than-expected data prompted a significant market rally, with the S&P 500, Dow, and Nasdaq all climbing as investors grew more optimistic. The prevailing view is that easing inflation gives the central bank room to lower interest rates. Lower rates typically reduce borrowing costs for businesses and make stocks more attractive relative to bonds, contributing to widespread gains across sectors like healthcare. The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Among others, the following stocks were impacted: Medical Devices & Supplies - Specialty company Inspire Medical Systems (NYSE:INSP) jumped 3%. Is now the time to buy Inspire Medical Systems? Access our full analysis report here, it's free. Drug Development Inputs & Services company UFP Technologies (NASDAQ:UFPT) jumped 3.5%. Is now the time to buy UFP Technologies? Access our full analysis report here, it's free. Medical Devices & Supplies - Specialty company Globus Medical (NYSE:GMED) jumped 3%. Is now the time to buy Globus Medical? Access our full analysis report here, it's free. Medical Devices & Supplies - Diversified company Neogen (NASDAQ:NEOG) jumped 3.4%. Is now the time to buy Neogen? Access our full analysis report here, it's free. Dental Equipment & Technology company Dentsply Sirona (NASDAQ:XRAY) jumped 3.1%. Is now the time to buy Dentsply Sirona? Access our full analysis report here, it's free. Zooming In On UFP Technologies (UFPT) UFP Technologies's shares are very volatile and have had 24 moves greater than 5% over the last year. In that context, today's move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business. The previous big move we wrote about was 7 days ago when the stock gained 11.9% on the news that the company posted record second-quarter results and beat analyst profit expectations. The medical products company reported a 37.2% surge in sales to $151.2 million compared to the same period last year. Its adjusted earnings per share reached $2.50, which surpassed Wall Street's consensus estimate of $2.25. This strong performance was primarily driven by a 46% jump in its MedTech business, fueled by demand in areas like robotic-assisted surgery. However, the results included a 20% decline in its Advanced Components division, and the company noted increased labor costs pressured margins. UFP Technologies is down 10.2% since the beginning of the year, and at $221.03 per share, it is trading 38.3% below its 52-week high of $358.42 from September 2024. Investors who bought $1,000 worth of UFP Technologies's shares 5 years ago would now be looking at an investment worth $5,057. Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story.

Expedia Group Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags
Expedia Group Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags

Yahoo

time22 minutes ago

  • Yahoo

Expedia Group Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags

Explore Expedia Group's Fair Values from the Community and select yours Expedia Group (NASDAQ:EXPE) Second Quarter 2025 Results Key Financial Results Revenue: US$3.79b (up 6.4% from 2Q 2024). Net income: US$330.0m (down 14% from 2Q 2024). Profit margin: 8.7% (down from 11% in 2Q 2024). The decrease in margin was driven by higher expenses. EPS: US$2.61 (down from US$2.93 in 2Q 2024). This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. All figures shown in the chart above are for the trailing 12 month (TTM) period Expedia Group Revenues Beat Expectations, EPS Falls Short Revenue exceeded analyst estimates by 2.0%. Earnings per share (EPS) missed analyst estimates by 25%. Looking ahead, revenue is forecast to grow 6.0% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Hospitality industry in the US. Performance of the American Hospitality industry. The company's shares are up 4.1% from a week ago. Balance Sheet Analysis While earnings are important, another area to consider is the balance sheet. We have a graphic representation of Expedia Group's balance sheet and an in-depth analysis of the company's financial position. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Bruker, Viatris, Sotera Health Company, Align Technology, and Omnicell Stocks Trade Up, What You Need To Know
Bruker, Viatris, Sotera Health Company, Align Technology, and Omnicell Stocks Trade Up, What You Need To Know

Yahoo

time22 minutes ago

  • Yahoo

Bruker, Viatris, Sotera Health Company, Align Technology, and Omnicell Stocks Trade Up, What You Need To Know

What Happened? A number of stocks jumped in the afternoon session after positive inflation data fueled hopes for an interest rate cut by the Federal Reserve. The latest Consumer Price Index (CPI) report showed inflation rose by a modest 0.2% in July and 2.7% over the last year. This cooler-than-expected data prompted a significant market rally, with the S&P 500, Dow, and Nasdaq all climbing as investors grew more optimistic. The prevailing view is that easing inflation gives the central bank room to lower interest rates. Lower rates typically reduce borrowing costs for businesses and make stocks more attractive relative to bonds, contributing to widespread gains across sectors like healthcare. The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Among others, the following stocks were impacted: Research Tools & Consumables company Bruker (NASDAQ:BRKR) jumped 3.7%. Is now the time to buy Bruker? Access our full analysis report here, it's free. Generic Pharmaceuticals company Viatris (NASDAQ:VTRS) jumped 3.1%. Is now the time to buy Viatris? Access our full analysis report here, it's free. Research Tools & Consumables company Sotera Health Company (NASDAQ:SHC) jumped 3.1%. Is now the time to buy Sotera Health Company? Access our full analysis report here, it's free. Dental Equipment & Technology company Align Technology (NASDAQ:ALGN) jumped 3.3%. Is now the time to buy Align Technology? Access our full analysis report here, it's free. Healthcare Technology for Providers company Omnicell (NASDAQ:OMCL) jumped 3.1%. Is now the time to buy Omnicell? Access our full analysis report here, it's free. Zooming In On Bruker (BRKR) Bruker's shares are very volatile and have had 20 moves greater than 5% over the last year. In that context, today's move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business. The previous big move we wrote about was 8 days ago when the stock dropped 7.4% on the news that the company reported disappointing second-quarter results and lowered its full-year financial forecast, citing challenging market demand. The company's revenue for the quarter landed at $797.4 million, which missed analyst expectations. A key metric, organic revenue, which measures sales growth from a company's core operations, fell by 7.0%. Earnings per share (EPS), a measure of profitability, came in at $0.32, significantly below the consensus estimate of $0.42. In response to the weak performance, Bruker cut its full-year guidance, and now projected an organic revenue decline between 2% and 4%. Management pointed to decreased demand for life-science research instruments, especially from U.S. academic and biopharma customers, as the primary cause. The company also announced a cost-saving plan intended to reduce annual expenses. Bruker is down 45.9% since the beginning of the year, and at $31.80 per share, it is trading 55% below its 52-week high of $70.67 from September 2024. Investors who bought $1,000 worth of Bruker's shares 5 years ago would now be looking at an investment worth $723.25. Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store